Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Holdings

2,400.74
+17.940.75%
Number of Gainers:71
Number of Losers:26
Number of Flat:- -
PE:- -
High:2,401.74
Open:2,383.00
Low:2,383.00
Close:2,382.78
Volume:789.89M
Turnover:155.40B
Market Cap:53.20T
Float Cap:49.82T

Loading ...

Google Cloud, Balyasny Asset Management Partner to Deploy Gemini Models in Financial Research Platform

Reuters
·
Oct 08

J.P. Morgan Remains a Sell on USA Compression (USAC)

TIPRANKS
·
Oct 08

Bristol-Myers Squibb (BMY) Receives a Buy from J.P. Morgan

TIPRANKS
·
Oct 08

Cantor Fitzgerald Adjusts Price Target on Pfizer to $28 From $27

MT Newswires Live
·
Oct 08

Eni Affiliate Eni CCUS Holding Says Liverpool Bay CCS Installs Douglas Offshore CO2 Storage Platform

Reuters
·
Oct 08

U.S. Stocks on the MOVE-Royal Caribbean, Generac

Reuters
·
Oct 08

SAP SE (SAP): New Buy Recommendation for This Technology Giant

TIPRANKS
·
Oct 08

Tesla's Big AI Gamble Puts Its EV Business Under a Microscope

Dow Jones
·
Oct 08

Tesco Wins Buy Rating on Earnings Beat, Upgraded Profit Guidance and Expanded Buyback Programme

TIPRANKS
·
Oct 08

How to invest in healthcare stocks without picking the next Eli Lilly

Simply Wall St.
·
Oct 08

OpenAI Rolls Out GPT-6 With Intelligent UI Capability to All ChatGPT Users

MT Newswires Live
·
Oct 08

Barclays Adjusts Price Target on PayPal Holdings to $56 From $57

MT Newswires Live
·
Oct 08

Italy Launches EU-Backed Probe into Microsoft-Owned Gaming Companies

Reuters
·
Oct 08

Bristol Myers’ zenbexus in combination shows efficacy in Phase 3 myeloma trial

TIPRANKS
·
Oct 08

JPMorgan Trims Stake in Anker Innovations (00668) by About 43,700 Shares at Roughly HK$113.65 Each

Stock News
·
Oct 08

Why Nvidia and AMD Stocks Are Edging Lower Today (October 8) — and What Analysts Expect Next

TIPRANKS
·
Oct 08

PepsiCo, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Oct 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH)

TIPRANKS
·
Oct 08

Bristol Myers Squibb Says Zenbexus Combo Cuts Multiple Myeloma Progression Risk 51% in Phase 3 Excaliber-RRMM Trial

Reuters
·
Oct 08

Bristol Myers Squibb Announces Zenbexustm (Iberdomide) in Combination with Daratumumab and Dexamethasone (Zdd) Demonstrates Superior Progression-Free Survival VS. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

THOMSON REUTERS
·
Oct 08